RPID

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems NASDAQ: RPID reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company's prior guidance, as consumable sales, service activity and recurring revenue increased.

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Reports  second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter 2026 Second quarter consumable revenue increased more than 20% year-over-year Second quarter recurring revenue increased 14% year-over-year; comprised 63% of total revenue Reports record second quarter total gross margin of 15% , an increase of 11 percentage points compared to the  second quarter of 2025 Merck MilliporeSigma to host European Growth Direct Day in October 2026, supporting customer engagement, education, and commercial pipeline development across Europe Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million, including 30 to 38 Growth Direct system placements Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with second half 2026 margins in the mid-20% range LEXINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2026.

LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on August 3, 2026, of 90,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) and a non-qualified stock option to purchase 170,000 shares of Common Stock (the “Option”), all as a material inducement to employment for a new employee. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.

LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2026 financial results prior to the market open on Friday, August 7, 2026.

LEXINGTON, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grant on June 3, 2026, of 60,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) as a material inducement to employment for a new employee. Such equity award was made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and was approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable RSU award agreement covering the grant.

Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering

Rapid Micro Biosystems NASDAQ: RPID reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while management said gross margin improvement remains a central priority for the year.